Markets:

Overview

News

Currencies

International

Treasuries

Tema Heart & Health ETF (NQ:HRTS)

35.44 -0.07 (-0.20%)

Streaming Delayed Price Updated: 3:42 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Tema Heart & Health ETF

Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing ↗

February 13, 2025

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

Via Stocktwits

Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes ↗

January 15, 2025

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

Via Stocktwits

EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss ↗

December 20, 2024

Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted.

Via Benzinga

EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' ↗

September 25, 2024

Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line.

Via Benzinga

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗

July 18, 2024

Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.

Via Benzinga

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO ↗

July 07, 2024

The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.

Via Benzinga

Topics ETFs

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗

July 05, 2024

A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.

Via Investor's Business Daily

Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply ↗

May 29, 2024

The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to...

Via Benzinga

Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test ↗

April 17, 2024

The results also pressured ResMed, a maker of CPAPs. CPAPs are the common treatment for sleep apnea.

Via Investor's Business Daily

Healthcare ETFs For The Weight-Loss Drug Boom And Beyond ↗

April 08, 2024

Two dominant investing themes over the past year have been AI and weight-loss drugs.

Via Talk Markets

Topics Artificial Intelligence ETFs

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing ↗

January 29, 2024

David Song, PM of the Cardiovascular and Metabolic ETF (NASDAQ: HRTS) for Tema ETFs, was recently interviewed by Benzinga.

Via Benzinga

Topics ETFs

Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market ↗

December 04, 2023

Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic

Via Benzinga

EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads ↗

December 01, 2023

Tema ETFs is redefining thematic investing, focusing on long-term structural trends & precision in security selection rather than chasing short-term fads.

Via Benzinga

Topics ETFs

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.